CheckMate 8HW: Nivo/Ipi Versus Nivo Alone for MSI-H/dMMR mCRC

Christopher Lieu, MD, of University of Colorado Medicine, breaks down the CheckMate 8HW trial on nivolumab plus ipilimumab versus nivolumab monotherapy for metastatic colorectal cancer.

Presented at ASCO GI 2025, the combination was shown to provide a 71% response rate, pointing to a new potential treatment for this patient population.